Multiple interaction sites of galnon trigger its biological effects

A Florén, U Sollenberg, L Lundström, M Zorko, J Stojan… - Neuropeptides, 2005 - Elsevier
Galnon was first reported as a low molecular weight non-peptide agonist at galanin
receptors [Saar et al.(2002) Proc. Natl. Acad. Sci. USA 99, 7136–7141]. Following its
systemic administration, this synthetic ligand affected a range of important physiological
processes including appetite, seizures and pain. Physiological activity of galnon could not
be explained solely by the activation of the three known galanin receptors, GalR1, GalR2
and GalR3. Consequently, it was possible that galnon generates its manifold effects by …